Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$295.00|
|52 Week High||NT$216.00|
|52 Week Low||NT$450.00|
|1 Month Change||-1.83%|
|3 Month Change||-21.65%|
|1 Year Change||1.72%|
|3 Year Change||1,000.75%|
|5 Year Change||1,208.20%|
|Change since IPO||1,379.52%|
Recent News & Updates
|3218||TW Healthcare||TW Market|
Return vs Industry: 3218 exceeded the TW Healthcare industry which returned -5.5% over the past year.
Return vs Market: 3218 underperformed the TW Market which returned 33.6% over the past year.
Stable Share Price: 3218 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 3218's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
|1992||n/a||Zheng Hong Lu||https://www.eyecenter.com.tw|
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and internationally. Its clinics provide laser vision correction surgery for myopia, hyperopia, astigmatism, and presbyopia; intraocular lens surgery for presbyopia and cataract; phacoemulsification and femtosecond laser for cataract surgery; and myopia control services, as well as services for dry eyes, retinal detachment, macular degeneration, strabismus, amblyopia, and other eye diseases. The company also offers vision products and services, including wide eyeglass frames, multifocal and progressive lenses for myopia and presbyopia, sunglasses, orthokeratology, rigid gas permeable lenses, regular/colored contact lenses, eye supplements, etc.,; eye plastic and micro cosmetic surgery; and customized aesthetic medicine consulting.
Is Universal Vision Biotechnology undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 3218 (NT$295) is trading below our estimate of fair value (NT$555.07)
Significantly Below Fair Value: 3218 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 3218 is poor value based on its PE Ratio (40.4x) compared to the TW Healthcare industry average (18.2x).
PE vs Market: 3218 is poor value based on its PE Ratio (40.4x) compared to the TW market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: 3218 is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: 3218 is overvalued based on its PB Ratio (12x) compared to the TW Healthcare industry average (1.8x).
How is Universal Vision Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3218's forecast earnings growth (31.2% per year) is above the savings rate (0.8%).
Earnings vs Market: 3218's earnings (31.2% per year) are forecast to grow faster than the TW market (8.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 3218's revenue (20.8% per year) is forecast to grow faster than the TW market (9.5% per year).
High Growth Revenue: 3218's revenue (20.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3218's Return on Equity is forecast to be high in 3 years time (34.8%)
How has Universal Vision Biotechnology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3218 has high quality earnings.
Growing Profit Margin: 3218's current net profit margins (23.2%) are higher than last year (19.8%).
Past Earnings Growth Analysis
Earnings Trend: 3218's earnings have grown significantly by 40.5% per year over the past 5 years.
Accelerating Growth: 3218's earnings growth over the past year (72.5%) exceeds its 5-year average (40.5% per year).
Earnings vs Industry: 3218 earnings growth over the past year (72.5%) exceeded the Healthcare industry -2.8%.
Return on Equity
High ROE: 3218's Return on Equity (28.7%) is considered high.
How is Universal Vision Biotechnology's financial position?
Financial Position Analysis
Short Term Liabilities: 3218's short term assets (NT$1.8B) exceed its short term liabilities (NT$952.0M).
Long Term Liabilities: 3218's short term assets (NT$1.8B) exceed its long term liabilities (NT$603.0M).
Debt to Equity History and Analysis
Debt Level: 3218's debt to equity ratio (19.9%) is considered satisfactory.
Reducing Debt: 3218's debt to equity ratio has increased from 19.7% to 19.9% over the past 5 years.
Debt Coverage: 3218's debt is well covered by operating cash flow (181.1%).
Interest Coverage: 3218's interest payments on its debt are well covered by EBIT (102.1x coverage).
What is Universal Vision Biotechnology current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 3218's dividend (1.42%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (1.93%).
High Dividend: 3218's dividend (1.42%) is low compared to the top 25% of dividend payers in the TW market (5.25%).
Stability and Growth of Payments
Stable Dividend: 3218 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 3218's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (57.5%), 3218's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 3218's dividends in 3 years are forecast to be covered by earnings (60.5% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Zheng Hong Lu
Zheng Hong Lu serves as the General Manager of Universal Vision Biotechnology Co., Ltd.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Universal Vision Biotechnology Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Universal Vision Biotechnology Co., Ltd.
- Ticker: 3218
- Exchange: TPEX
- Founded: 1992
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: NT$22.456b
- Shares outstanding: 76.12m
- Website: https://www.eyecenter.com.tw
Number of Employees
- Universal Vision Biotechnology Co., Ltd.
- No.3-1 Yuanqu Street
- 4th Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/20 08:32|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.